News Image

Is NASDAQ:AMPH a Fit for Growth Investing Strategies?

By Mill Chart

Last update: Feb 14, 2024

Growth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) is suited for growth investing. Investors should of course do their own research, but we spotted AMPHASTAR PHARMACEUTICALS IN showing up in our Louis Navellier growth screen, so it may be worth spending some more time on it.

A Deep Dive into AMPHASTAR PHARMACEUTICALS IN's Growth Metrics.

  • With a solid Return on Equity (ROE) of 22.72%, AMPHASTAR PHARMACEUTICALS IN exemplifies its ability to generate favorable returns on shareholder investments. This metric demonstrates the company's commitment to maximizing shareholder value.
  • AMPHASTAR PHARMACEUTICALS IN has a strong history of beating EPS estimates in the last 4 quarters, signaling its ability to consistently exceed market expectations. This indicates the company's strong financial performance and its potential for creating shareholder value.
  • AMPHASTAR PHARMACEUTICALS IN has achieved significant 1-year revenue growth of 24.0%, signaling its ability to capture market opportunities and drive top-line expansion. This growth indicates the company's effective execution and its potential for continued success.
  • AMPHASTAR PHARMACEUTICALS IN has experienced 50.37% q2q revenue growth, indicating a significant sales increase.
  • With a favorable trend in its operating margin over the past year, AMPHASTAR PHARMACEUTICALS IN demonstrates its ability to enhance profitability through efficient operations. This growth reflects the company's focus on optimizing its cost structure.
  • With a favorable trend in its free cash flow (FCF) over the past year, AMPHASTAR PHARMACEUTICALS IN demonstrates its ability to generate robust cash flows and maintain financial stability. This growth reflects the company's focus on efficient capital allocation and cash management.
  • In the most recent financial report, AMPHASTAR PHARMACEUTICALS IN reported a 203.0% increase in quarterly earnings compared to the previous quarter. This notable growth indicates positive momentum in the company's financials, suggesting an upward trend
  • AMPHASTAR PHARMACEUTICALS IN has seen a 23.76% change in the average next Quarter EPS Estimate by analysts over the last 3 months, signaling the shifting perception of the company's EPS outlook.
  • The quarterly earnings of AMPHASTAR PHARMACEUTICALS IN have shown a 203.0% increase compared to the previous quarter, as revealed in the recent financial report. This growth signifies positive momentum in the company's financials, pointing towards a promising upward trend
  • AMPHASTAR PHARMACEUTICALS IN shows accelerating EPS growth: when comparing the current Q2Q growth of 203.0% to the previous year Q2Q growth of -17.39%, we see the growth rate improving.

A complete fundamental analysis of NASDAQ:AMPH

ChartMill assigns a Fundamental Rating to every stock. This score, ranging from 0 to 10, is updated daily and is determined by evaluating multiple fundamental indicators and properties.

AMPH gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 204 industry peers in the Pharmaceuticals industry. While AMPH has a great profitability rating, there are some minor concerns on its financial health. AMPH is growing strongly while it also seems undervalued. This is an interesting combination This makes AMPH very considerable for value and growth investing!

Check the latest full fundamental report of AMPH for a complete fundamental analysis.

More growth stocks can be found in our Lois Navellier screen.

Keep in mind

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

AMPHASTAR PHARMACEUTICALS IN

NASDAQ:AMPH (5/24/2024, 7:13:49 PM)

After market: 43 -0.26 (-0.6%)

43.26

-0.09 (-0.21%)

AMPH News

News Image11 days ago - InvestorPlacePatent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade

The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.

News Image12 days ago - ChartmillExploring NASDAQ:AMPH's growth characteristics.

AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) showing high EPS and FCF growth while beating expectations

News Image18 days ago - InvestorPlaceAMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024

AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

News Image18 days ago - BusinessInsiderAMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amphastar Pharma (NASDAQ:AMPH) just reported results for the first quarter of 2...

News Imagea month ago - Market News VideoOversold Conditions For Amphastar Pharmaceuticals (AMPH)
News Imagea month ago - Market News VideoCommit To Buy Amphastar Pharmaceuticals At $22.50, Earn 18.5% Annualized Using Options
News Image3 months ago - Market News VideoAmphastar Pharmaceuticals Becomes Oversold (AMPH)
News Image3 months ago - Market News VideoAmphastar Pharmaceuticals (AMPH) Shares Cross Below 200 DMA
News Image3 months ago - Seeking AlphaAmphastar Pharmaceuticals Non-GAAP EPS of $0.88 misses by $0.03, revenue of $178.1M beats by $4.77M (NASDAQ:AMPH)

Amphastar Pharmaceuticals reports Q4 financial results with a Non-GAAP EPS of $0.88, missing estimates by $0.03, while revenue of $178.1M beats expectations...

News Image3 months ago - Investor's Business DailyCRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+

CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

News Image4 months ago - Market News VideoAMPH Crosses Below Key Moving Average Level
News Image4 months ago - InvestorPlace3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential

As the new business cycle gets started, here are some biotech stocks with potential that investors should pay attention to.

AMPH Links
Follow us for more